Ketamin til akut depressionsbehandling

Ugeskrift for Laeger

Volumn 175, Issue 37, 2013, Pages 2090-2093

  Hjerrild, Simon ^a   Bjerre, Johannes ^b   Pedersen, Rasmus Hjuler ^a   Videbech, Poul ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b Psykiatrisk Afdeling Esbjerg Ribe   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84890585963     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Global burden of disease. Geneve: WHO, 2008.
2. Referenceprogram for behandling af unipolar depression hos voksne. Kobenhavn: Sundhedsstyrelsen, 2007.
3. Rush AJ, Trivedi MH, Wisniewski SR et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006;163:1905-17.
4. Sorensen AG, Barnung S, Rasmussen LS. Ketamin genopdaget af bade lager og misbrugere. Ugeskr Lager 2011;173:2123-6.
5. Duman RS, Voleti B. Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents. Trends Neurosci 2012;35:47-56.
6. Li N, Lee B, Liu RJ et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010;329:959-64.
7. Duncan WC, Sarasso S, Ferrarelli F et al. Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder. Int J Neuropsychopharmacol 2013;16:301-11.
8. Cornwell BR, Salvadore G, Furey M et al. Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression. Biol Psychiatry 2012;72:555-61.
9. Mathew SJ, Shah A, Lapidus K et al. Ketamine for treatment-resistant unipolar depression: current evidence. CNS Drugs 2012;26:189-204.
10. Berman RM, Cappiello A, Anand A et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000;47:351-4.
11. Zarate CAJ, Singh JB, Carlson PJ et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006;63:856-64.
12. Valentine GW, Mason GF, Gomez R et al. The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS. Psychiatry Res 2011;191:122-7.
13. Diazgranados N, Ibrahim L, Brutsche NE et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 2010;67:793-802.
14. Zarate CA Jr., Brutsche N, Laje G et al. Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression. Biol Psychiatry 2012;72:331-8.
15. Mathew SJ, Murrough JW, aan het Rot M et al. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol 2010;13:71-82.
16. Machado-Vieira R, Yuan P, Brutsche N et al. Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist. J Clin Psychiatry 2009;70:1662-6.
17. Phelps LE, Brutsche N, Moral JR et al. Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. Biol Psychiatry 2009;65:181-4.
18. aan het Rot M, Collins KA, Murrough JW et al. Safety and efficacy of repeateddose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 2010;67:139-45.
19. Price RB, Nock MK, Charney DS et al. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry 2009;66:522-6.
20. Larkin GL, Beautrais AL. A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int J Neuropsychopharmacol 2011;14:1127-31.
21. Ibrahim L, Diazgranados N, Luckenbaugh DA et al. Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:1155-9.
22. Ibrahim L, Diazgranados N, Franco-Chaves J et al. Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology 2012;37:1526-33.
23. Okamoto N, Nakai T, Sakamoto K et al. Rapid antidepressant effect of ketamine anesthesia during electroconvulsive therapy of treatment-resistant depression: comparing ketamine and propofol anesthesia. J ECT 2010;26:223-7.
24. Kranaster L, Kammerer-Ciernioch J, Hoyer C et al. Clinically favourable effects of ketamine as an anaesthetic for electroconvulsive therapy: a retrospective study. Eur Arch Psychiatry Clin Neurosci 2011;261:575-82.
25. Krystal AD, Weiner RD, Dean MD et al. Comparison of seizure duration, ictal EEG, and cognitive effects of ketamine and methohexital anesthesia with ECT. J Neuropsychiatry Clin Neurosci 2003;15:27-34.
26. McDaniel WW, Sahota AK, Vyas BV et al. Ketamine appears associated with better word recall than etomidate after a course of 6 electroconvulsive therapies. J ECT 2006;22:103-6.
27. www.medicin.dk (12. dec 2012).
28. Winstock AR, Mitcheson L. New recreational drugs and the primary care approach to patients who use them. BMJ 2012;344:e288.
29. Middela S, Pearce I. Ketamine-induced vesicopathy: a literature review. Int J Clin Pract 2011;65:27-30.